SCHEMBL5584694

SCHEMBL5584694

COc1ccc2c(Cl)c(C(=O)N(C)C)sc2c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.70
RXFP1 Q9HBX9 2/20 0.70
NPSR1 Q6W5P4 2/20 0.70
PRNP P04156 1/20 0.70
TSHR P16473 1/20 0.70
PPARG P37231 1/20 0.70
HTT P42858 1/20 0.70
MAPK10 P53779 1/20 0.70
NCOA2 Q15596 1/20 0.70
DYRK1A Q13627 2/20 0.68
MAPT P10636 6/20 0.65
ALDH1A1 P00352 6/20 0.65
KDM4E B2RXH2 3/20 0.65
GAA P10253 2/20 0.65
LMNA P02545 1/20 0.65
SMN1; SMN2 Q16637 4/20 0.65
HPGD P15428 3/20 0.52
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
POLB P06746 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18940235 0.89 MAPK1 (0.67) MAPK1RXFP1NPSR1PRNPTSHR
SCHEMBL5453267 0.84 RXFP1 (0.76) MAPK1RXFP1NPSR1PRNPTSHR
SCHEMBL3102501 0.84 RXFP1 (0.76) MAPK1RXFP1NPSR1PRNPTSHR
SCHEMBL18960346 0.84 RXFP1 (0.76) MAPK1RXFP1NPSR1PRNPTSHR
Ammonia Solution, Strong SCHEMBL28931345 0.82 RXFP1 (0.74) MAPK1RXFP1NPSR1PRNPTSHR
SCHEMBL8412494 0.82 NPSR1 (0.74) MAPK1RXFP1NPSR1PRNPTSHR
SCHEMBL27776911 0.81 DYRK1A (1.00) MAPK1RXFP1NPSR1PRNPTSHR
SCHEMBL18940219 0.80 PRNP (0.70) MAPK1RXFP1NPSR1PRNPTSHR
SCHEMBL18970426 0.80 MAPT (0.78) MAPK1RXFP1NPSR1PRNPTSHR
SCHEMBL5584892 0.80 DYRK1A (0.50) MAPK1RXFP1NPSR1PRNPTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7196199-B2 Antiserotonine agents; antidepressants MITSUBISHI PHARMA CORPORATION (JP) 2007-03-27 US disclosed
US-7196199-B2 Antiserotonine agents; antidepressants MITSUBISHI PHARMA CORPORATION (JP) 2007-03-27 US disclosed
US-7196199-B2 Antiserotonine agents; antidepressants MITSUBISHI PHARMA CORPORATION (JP) 2007-03-27 US disclosed
EP-1188747-B1 PHENOXYPROPYLAMINE COMPOUNDS MITSUBISHI PHARMA CORP (JP) 2005-09-07 EP disclosed
US-20040138227-A1 Phenoxypropylamine compounds NISHIYAMA AKIRA 2004-07-15 US disclosed
US-6720320-B2 ANTISEROTONINE AGENTS MITSUBISHI PHARMA CORPORATION (JP) 2004-04-13 US disclosed
US-20020111358-A1 Phenoxypropylamine compounds MITSUBISHI PHARMA CORPORATION (JP) 2002-08-15 US disclosed
EP-1188747-A1 PHENOXYPROPYLAMINE COMPOUNDS Mitsubishi Pharma Corporation (JP) 2002-03-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138227-A1 Phenoxypropylamine compounds HTR1A, HTR1D, HTR5A MAPK1 163/4885RXFP1 561/4885NPSR1 38/4885
US-20020111358-A1 Phenoxypropylamine compounds HTR1A, HTR1D, HTR5A MAPK1 163/4885RXFP1 561/4885NPSR1 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.